A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.


Updates from The Motley Fool

Latest updates on Valeant Pharmaceuticals from Fool.com.  The Fool has written over 300 articles on Valeant Pharmaceuticals.
3 Tempting Stocks We're Avoiding

Image source: Getty Images. Have you ever come across a company that seemed like too good of a va...

Top Biotech Resolutions for 2017

Battered by bad news, beaten-up biopharma has some work to do to restore investor confidence in 2...



Stock Performance

View Interactive VRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Valeant Pharmaceuticals.
Current Price: $15.24
Prev Close: $15.33
Open: $15.30
Bid: $15.30
Ask: $15.33
Day's Range: $15.00 - $15.67
52wk Range: $13.00 - $101.40
Volume: 10,221,697
Avg Vol 15,751,221
Market Cap: $5B
P/E (ttm): -4.99
EPS (ttm): ($3.07)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Valeant Pharmaceuticals.
CAPS Rating 3 out of 5
 
508 Outperform
73 Underperform
CAPS All Stars
 
106 Outperform
24 Underperform

How do you think Valeant Pharmaceuticals will perform against the market?



You pick for Valeant Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Joseph C. Papa, CEO

0% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Valeant Pharmaceuticals.

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers